This is an open label, phase III study evaluating the efficacy and safety of Pyrotinib in Combination With Trastuzumab and paclitaxel in patients HER2 Positive and lymph node negative invasive Breast Cancer
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
876
pyrotinib: 400mg orally daily for 1 year
8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
80mg/m2 per week for a total of 12 weeks
Disease free survival
Time frame: 5 year
distant recurrence free survival
Time frame: 5 year
overall survival
Time frame: 5 year
adverse effects
Time frame: 5 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.